Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0001271

Aciclovir for peak identification 1

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Acycloguanosine, 9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C8H11N5O3
Número de CAS:
59277-89-3
Peso molecular:
225.20
Número MDL:
MFCD00057880
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831334
NACRES:
NA.24

grado

pharmaceutical primary standard

descripción

API family: acyclovir

familia API

acyclovir

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

Clave InChI

MKUXAQIIEYXACX-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Aciclovir for peak identification 1 EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

A0220000

Aciclovir, European Pharmacopoeia (EP) Reference Standard

1012065

Acyclovir, United States Pharmacopeia (USP) Reference Standard

1012076

Acyclovir Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1254

Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001264

Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard

1012087

Acyclovir Related Compound G, United States Pharmacopeia (USP) Reference Standard

1012054

Acyclovir Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP438

Aciclovir, British Pharmacopoeia (BP) Reference Standard

Y0002245

Aciclovir for system suitability A, CRS, European Pharmacopoeia (EP) Reference Standard

Y0002244

Aciclovir for impurity G identification, European Pharmacopoeia (EP) Reference Standard

Y0002242

Aciclovir for impurity C identification, CRS, European Pharmacopoeia (EP) Reference Standard

Código de clase de almacenamiento

13 - Non Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Martina Prelog et al.
Pediatric nephrology (Berlin, Germany), 26(5), 663-673 (2010-11-16)
Clear recommendations for the management of acute varicella-zoster virus (VZV) infections for cases of significant exposure and the use of prophylactic drugs after solid-organ transplantation are missing due to the lack of evidence by prospective studies. Heterogeneity in patient groups
Todd Hatchette et al.
The Pediatric infectious disease journal, 27(1), 75-77 (2007-12-29)
The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A
Suneel Chilukuri et al.
Dermatologic clinics, 21(2), 311-320 (2003-05-22)
In immunocompetent patients, HSV is controlled rapidly by the human host's immune system, and recurrent lesions are small and short lived. When treated with antiviral agents, these patients rarely develop resistance to these drugs. In contrast immunocompromised patients might not
Josef Haik et al.
Journal of burn care & research : official publication of the American Burn Association, 32(3), 358-362 (2011-03-24)
Both cosmetic facial resurfacing and facial burns cause an injury to the dermal layer of the skin. This injury renders the patient susceptible to primary herpes simplex virus (HSV) infection or, more commonly, to HSV reactivation. This in turn can
Jeanne S Sheffield et al.
Obstetrics and gynecology, 102(6), 1396-1403 (2003-12-10)
Genital herpes simplex virus (HSV) infection is one of the most common viral sexually transmitted diseases in the United States. Perinatal transmission of the virus to the fetus or neonate is a major concern in affected pregnancies. Our objective was
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico